Navigation Links
Hiemstra Appoints Daniel C. Rosenman as Vice President of Research & Development
Date:3/25/2008

Furthers firm design and development efforts that focus on usability and

rapid commercialization

SAN FRANCISCO, March 25 /PRNewswire/ -- Hiemstra Product Development, an innovative, product design and development company, serving the life sciences industry, today announced the appointment of Daniel C. Rosenman as Vice President of Research & Development. As the company continues to expand, Dan furthers Hiemstra's commitment to the design and engineering of medical technologies that focus on usability and rapid commercialization.

Dan joins Hiemstra with over 16 years of R&D, operations, clinical, regulatory and quality systems experience in the life sciences industry. He has developed novel medical technologies in diverse clinical areas including general surgery, gynecology, orthopedics, urology, cardiac surgery, interventional cardiology, and ophthalmology, in both large companies and early-stage ventures. He began his life science career as an R&D engineer, specializing in bioabsorbable polymers, with Ethicon, Inc., a Johnson & Johnson company. Dan was one of the early employees at med tech start-ups, Heartport, Inc. and BioCardia, Inc., where he led the R&D efforts from the initial founding, to financing and through commercialization. Dan was the first employee at Transcend Medical, Inc., a venture-backed ophthalmic company. Within months of joining Transcend, he completed research, development and clinical milestones that resulted in series A funding. Dan holds over 27 U.S. patents in the medical field and has other global patents pending. He has co-authored several scientific and clinical publications in collaboration with clinical leaders at Stanford University, Massachusetts General Hospital, and HELIOS Hospital, Siegburg, Germany.

"My passion is to enable clients to develop their novel medical technologies for clinicians and, ultimately, patients," explains Rosenman. "At Hiemstra, our unique product development process delivers that. Our industrial and mechanical design teams are fully-integrated and focused on human factors that result in elegant solutions that go far beyond just clinical utility."

Doug Hiemstra, President, Hiemstra Product Development stated, "Dan adds tremendous value to our company and our customers. He brings a strong track record of successfully moving medical technologies from concept to development through commercialization."

About Hiemstra:

Hiemstra Product Development is an innovative medical product design and development company, serving the life sciences industry. Founded in 1991, this San Francisco-based firm is built on its unparalleled integration of industrial design and development, with a unique focus on usability. The company's production facilities provide for device assembly and rapid commercialization. Hiemstra's veteran team's experience spans a broad range of clinical areas and applications, and clients include start-ups to Fortune 500 companies. A description of services can be found at http://www.hiemstra.com.


'/>"/>
SOURCE Hiemstra Product Development
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Hiemstra Approved to Manufacture Medical Devices in New CER
2. AMICAS Appoints Joseph D. Hill to Its Board of Directors and Promotes Kevin C. Burns to Senior Vice President and Chief Financial Officer
3. Digirad Corporation Appoints John W. Sayward to Its Board of Directors
4. NutraCea Appoints New Chief Financial Officer
5. Transplant Network Appoints Cynthia Siljestrom CEO
6. Solera Holdings, Inc. Appoints Jason Brady as General Counsel
7. The Childrens Hospital of Philadelphia Appoints New Chief Nursing Officer
8. InnerPulse, Inc. Appoints Elsa Chi Abruzzo as Vice-President of Regulatory and Quality Affairs
9. Ventas Appoints James D. Shelton and Robert D. Reed to Board
10. Crdentia Appoints Randall Turnbull to Senior Vice President and Chief Clinical Officer
11. China Sky One Medical, Inc. Appoints Four Independent Board Members
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and ... of published author, William Nowers. Captain Nowers and his wife, Millie, have six ... years in the Navy. Following his career as a naval aviator and carrier ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... ... On Saturday, October 21, the Health & Wellness Center at Florida Hospital ... for the American Heart Association Heart Walk. Teams of up to 10 people can ... their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on Saturday, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical Officer Dr. ... colleagues, skilled nursing facility medical directors and other clinicians at various events in ... , "At many of these conferences we get to educate other physicians, facility ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Oct. 2, 2017  Eli Lilly and Company (NYSE: ... for the third quarter of 2017 on Tuesday, October ... on that day with the investment community and media ... The conference call will begin at 9 a.m. Eastern ... a live webcast of the conference call through a ...
(Date:9/28/2017)... 28, 2017 Cohen Veterans Bioscience and Early ... of wearable and home sensors for real-time monitoring of ... Foundation, a nonprofit organization focused on disruptive health solutions ... affordable analytical system to record and integrate behavioral, cognitive, ... ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
Breaking Medicine Technology: